Refine
Has Fulltext
- yes (185)
Is part of the Bibliography
- yes (185)
Year of publication
Document Type
- Journal article (185) (remove)
Language
- English (185) (remove)
Keywords
- CXCR4 (7)
- T cells (6)
- apoptosis (6)
- glioblastoma (6)
- immunohistochemistry (6)
- lymphoma (6)
- multiple myeloma (6)
- B cells (5)
- astrocytoma (5)
- cancer (5)
- gene expression (5)
- glioblastoma multiforme (5)
- recurrence (5)
- NFATc1 (4)
- brain (4)
- breast cancer (4)
- chemokine receptor (4)
- expression (4)
- forensic neuropathology (4)
- mRNA (4)
- machine learning (4)
- metastasis (4)
- prognosis (4)
- relapse (4)
- therapy (4)
- EGFR (3)
- Hodgkin lymphoma (3)
- MYC (3)
- NRF2 (3)
- PET/CT (3)
- biomarker (3)
- cerebrospinal fluid (3)
- forensic neurotraumatology (3)
- gene regulation (3)
- glioma (3)
- melanoma (3)
- neuronal differentiation (3)
- poor prognosis (3)
- positron emission tomography (3)
- protein (3)
- surgical oncology (3)
- ATF4 (2)
- BCL6 (2)
- CD30 (2)
- Cushing’s syndrome (2)
- DLBCL (2)
- EMT (2)
- Expression (2)
- FGFR (2)
- Glioblastoma (2)
- HNSCC (2)
- KEAP1 (2)
- MPS1 (2)
- Medizin (2)
- NAFLD (2)
- NASH (2)
- NFAT (2)
- NSCLC (2)
- Nfatc1 (2)
- PET (2)
- PTCL (2)
- Rhabdomyosarcoma (2)
- T-cell lymphoma (2)
- USP28 (2)
- adrenocortical carcinoma (2)
- alloreactive T cells (2)
- amplicon sequencing (2)
- angiogenesis (2)
- animal model (2)
- brain tumor (2)
- cancer stem cells (2)
- cancers and neoplasms (2)
- carcinomas (2)
- case report (2)
- cell staining (2)
- cell-cycle arrest (2)
- cytotoxic T cells (2)
- development (2)
- discriminant analysis (2)
- endothelial cells (2)
- enzyme-linked immunoassays (2)
- flow cytometry (2)
- gene (2)
- germinal center (2)
- imaging (2)
- immune response (2)
- immunohistochemistry techniques (2)
- in vivo imaging (2)
- inflammation (2)
- keratinocytes (2)
- kidneys (2)
- low-grade glioma (2)
- lung cancer (2)
- malignant tumors (2)
- messenger RNA (2)
- miRNA (2)
- mice (2)
- microenvironment (2)
- molecular diagnostics (2)
- molecular imaging (2)
- mouse models (2)
- mutations (2)
- neuroinflammation (2)
- obesity (2)
- organoids (2)
- plasma cells (2)
- positron emission tomography/computed tomography (2)
- postnatal development (2)
- principal component analysis (2)
- proteomics (2)
- radiotherapy (2)
- rat (2)
- receptor tyrosine kinases (2)
- regression analysis (2)
- survival (2)
- temozolomide (2)
- thymus (2)
- transcription (2)
- tumor microenvironment (2)
- vestibular schwannoma (2)
- vitamin D (2)
- 3D ex vivo models (1)
- 3D lung tumor tissue models (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AD-AID (1)
- ADAM9 (1)
- ADP-ribosylation toxins (1)
- AICDA (1)
- AID-ΔE4a (1)
- AKT-signaling (1)
- ALCL (1)
- ALK-1 (1)
- ATG7 (1)
- ATM (1)
- Activation (1)
- Adamantiades-Behçet disease (1)
- Adult (1)
- Alpha therapy (1)
- Antibodies (1)
- Antiparanodal Autoantibodies (1)
- Aphthae (1)
- Autoimmune diseases (1)
- B cell malignancies (1)
- B-MYB (1)
- B-cell lymphoma (1)
- B-cells (1)
- BIRC7 (1)
- Barrett-Ösophagus (1)
- Behçet’s disease (1)
- Bevacizumab (1)
- Bioluminescence imaging (1)
- Biomarker (1)
- Bone chips (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- Braak (1)
- Breast-cancer (1)
- Bruton Tyrosine Kinase (1)
- B‐cell lymphoma (1)
- C-Myc (1)
- C3 (1)
- CD/metabolism (1)
- CD117 (1)
- CD133 (1)
- CD274 (1)
- CD319 (1)
- CD40 ligand (1)
- CD56 (1)
- CD9 (1)
- CHAC1 (1)
- CK5 (1)
- COVID-19 (1)
- CRC (1)
- CRISPR-Cas9 (1)
- CRISPR/Cas9 (1)
- CS1 (1)
- CSF (1)
- CTNNB1 (1)
- CX5461 (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR2 (1)
- CXCR4/SDF-1 (1)
- CXCR7 (1)
- CYP24A1 (1)
- CYP2W1 (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer treatment (1)
- Chains (1)
- Chemotherapy (1)
- Childhood (1)
- Cisplatin (1)
- Clonality (1)
- Cushings syndrome (1)
- Cushing’s disease (1)
- DEL(5Q) (1)
- DHAP (1)
- DNA hypermethylation (1)
- DNA methylation (1)
- DNA-PK (1)
- DOTATOC (1)
- DT40 cells (1)
- DWI (1)
- Defined burkitts lymphoma (1)
- Delta Repertoire (1)
- Design (1)
- Diabetes mellitus (1)
- E-cadherin (1)
- EAHP/SH bone marrow workshop (1)
- EBER in situ hybridization (1)
- EBV (1)
- EGF (1)
- ERM proteins (1)
- EZH1 (1)
- EZH2 (1)
- Epidemiological study (1)
- Epitope (1)
- Epstein-Barr virus (1)
- Extraocular eye muscles (1)
- F-19 MRI (1)
- FADD (1)
- FARS1 (1)
- FDG PET/CT (1)
- FFPE (1)
- FGF-pathway (1)
- FINCA (1)
- FLT-PET (1)
- FTIR spectroscopy (1)
- Factor receptor (1)
- Fibrin glue (1)
- Frequency (1)
- GFAP (1)
- GIST (1)
- GLP-1 (1)
- GSH (1)
- Gene-expression (1)
- Genitoanal region (1)
- Genome wide analysis (1)
- Glioma stem cells (1)
- Graft-versus-leukemia (1)
- GvHD (1)
- H3K27me3 (1)
- HD (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- HNSC (1)
- HSC (1)
- Hans algorithm (1)
- Head (1)
- Head and neck cancers (1)
- High-resolution (1)
- Histone deacetylase inhibition (1)
- Hsp90 (1)
- Hypercortisolism (1)
- IDH (1)
- IDH1/2 (1)
- IFN (1)
- IFN-γ (1)
- IL-10 (1)
- IL-17 (1)
- IL-2 (1)
- IR (1)
- IRF4 (1)
- Ibrutinib (1)
- Images (1)
- Immunosuppression (1)
- Immunotherapy (1)
- In-vivo (1)
- Inflammation (1)
- Intestinal Intraepithelial Lymphocy (1)
- Iron-oxide (1)
- Irradiation (1)
- JUN (1)
- KIT (1)
- KRAS (1)
- KRAS biomarker signatures (1)
- Kaposi sarcoma (1)
- Kidney cancer (1)
- Krebs (1)
- LESA (1)
- LITAF (1)
- Lateral suboccipital craniectomy (1)
- Lesions (1)
- Ligand (1)
- Lipom (1)
- Lung-cancer (1)
- Lymph2Cx assay (1)
- Lymphoma (1)
- Lymphomas (1)
- MDS (1)
- MEK/ERK-signaling (1)
- MGMT (1)
- MGMT promoter methylation (1)
- MITF-low (1)
- MIZ1 (1)
- MTB (1)
- MTCH2 (1)
- MTX (1)
- Malignancies (1)
- Mantle cell lymphoma (1)
- Medical research (1)
- Merlin (1)
- Metastases (1)
- Microarray (1)
- Molecular pathogenesis (1)
- Multiple Myeloma (1)
- Myb-MuvB (1)
- Myeloma cells (1)
- Myelomas (1)
- NEC (1)
- NET (1)
- NF-KAPPA-B (1)
- NF-\(\kappa\)B pathway (1)
- NFE2L2 (1)
- NGS (1)
- NHLRC2 (1)
- NLPHL (1)
- NR3C1 (1)
- Nestin (1)
- Nodo-parandopathy (1)
- Nrf2 (1)
- Nuclear expression (1)
- OBF-1 OCA-B (1)
- OCT-1-deficient mice (1)
- OncotypeDX\(^{®}\) (1)
- Organoids (1)
- Osteogeneration (1)
- Osteopontin (1)
- PAI-1 (1)
- PCDHGC3 (1)
- PCI-32765 (1)
- PD-L1 (1)
- PI3K (1)
- PLAG1 rearrangement (1)
- PRRT (1)
- PTEN (1)
- Parkinson (1)
- Parkinsons disease (1)
- Parkinson’s disease (1)
- Particles (1)
- Pathway (1)
- Pentixafor (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- Pou2af1 (1)
- Profiling (1)
- Prognosis (1)
- Proliferation (1)
- Promoter (1)
- R-CHOP (1)
- RCC (1)
- RNA Expression (1)
- RNA probe (1)
- RNAPOL1 (1)
- RNAScope (1)
- RYGB (1)
- Rats (1)
- Regulatory-cells (1)
- Renal cell carcinoma (1)
- Rheumatoid arthritis (1)
- Rho-GTPases (1)
- Rituximab plus (1)
- Riutximab (1)
- SARS-CoV-2 (1)
- SB332235 (1)
- SGN-35 (1)
- SLC7A11 (1)
- SOAT1 (1)
- SSTR (1)
- Soft-tissue infection (1)
- Sox9 (1)
- SphK1 (1)
- Spinal dissemination (1)
- Spindle cell (1)
- Spleen (1)
- Sprue (1)
- Sunitinib (1)
- Suppression (1)
- Surgery (1)
- Survival (1)
- T cell differentiation (1)
- T cell receptors (1)
- T(H)17 cells (1)
- T-cell non-Hodgkin's lymphomas (1)
- T-cell transfer (1)
- T-follicular regulatory cell (1)
- TCR signaling cascade (1)
- TGF-alpha (1)
- TP53 (1)
- TP53 mutations (1)
- TTK (1)
- T\(_{reg}\) and Foxp3 (1)
- Targeted Therapies (1)
- Targets (1)
- Temozolomide (1)
- Th17 (1)
- Tracking (1)
- Transcription-factor (1)
- Translational research (1)
- Tregs (1)
- Tumor Microenvironment (1)
- Tumor Treating Fields (TTFields) (1)
- Tumor-necrosis-factor (1)
- Tumour markers (1)
- Tyrosine kinase inhibition (1)
- UMAP (1)
- USP8 (1)
- USP9X (1)
- Usage (1)
- Uveitis (1)
- VDR (1)
- WNT signaling (1)
- WTAP (1)
- Waldeyer’s tonsillar ring (1)
- Wilms tumour (1)
- XIAP (1)
- YAP (1)
- [18F]FDG-PET-CT (1)
- [18F]Fluorodeoxythymidine (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{68}\)Ga-Pentixafor (1)
- abdominal lymph node metastases (1)
- abnormalities (1)
- actin (1)
- actin filament (1)
- actin filaments (1)
- activation (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute lymphoblastic leukemia (1)
- acute lymphocytic leukaemia (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adenomas (1)
- adenosine kinase (1)
- adhesion (1)
- adrenal glands (1)
- adrenal tumor (1)
- adrenocortical (1)
- adrenocortical cancer (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- aggressive B‐cell lymphoma (1)
- allergy (1)
- alternative splicing (1)
- aluminum granuloma (1)
- aminoacyl‐tRNA synthetases (1)
- amplifications (1)
- amyloidoma (1)
- amyloidosis (1)
- anaplasia (1)
- anaplastic large cell lymphoma (1)
- anaplastic large cell lymphoma (ALCL) (1)
- anaplastic medulloblastoma (1)
- annecin-V (1)
- anti-CD30 drug conjugate (1)
- antibodies (1)
- antigen (1)
- antigen loss (1)
- antigens (1)
- antioxidant function (1)
- aortic adventitia (1)
- apoptosis, Myc (1)
- arteriovenous loop (1)
- atopic dermatitis (1)
- atrial natriuretic peptide (1)
- aurora kinase A polymorphism (1)
- aurorakinase B (1)
- autoantibodies (1)
- autoantigen (1)
- autoimmune disease (1)
- autologous transplantation (1)
- autophagy (1)
- axonally transported proteins (1)
- azacitidine (1)
- bacterial toxins (1)
- behavior (1)
- benige tumor (1)
- beta-catenin (1)
- binding (1)
- binding proteins (1)
- biofluid (1)
- bioinformatic clustering (1)
- biological sciences (1)
- biomarker prediction (1)
- biosynthesis (1)
- blood–brain barrier (1)
- bone disease (1)
- bone marrow biopsy (1)
- bone marrow cells (1)
- bone marrow–spleen–liver large B‐cell lymphoma (1)
- bone metastasis (1)
- boolean in silico models (1)
- botulinum C2 toxin (1)
- buparlisib (1)
- c-MYC (1)
- c-myc (1)
- cancer care (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer of unknown primary (CUP) (1)
- cancer treatment (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac transplantation (1)
- cardiomyocyte proliferation (1)
- caspase-3 (1)
- catenin (1)
- caveolin-1 (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell death (1)
- cell of origin (1)
- cells (1)
- cellular uptake (1)
- cerebellum (1)
- cerebral cortex (1)
- cerebropulmonary disease (1)
- cetuximab (1)
- checkpoint inhibition (1)
- chemokine (1)
- chemokine receptor-4 (1)
- childhood interstitial lung disease (1)
- children (1)
- children´s interstitial lung disease (chILD) lipoid pneumonia (1)
- cholesterol pneumonia (1)
- cholesterol pneumonitis (1)
- chromatin (1)
- chromosomal aberration (1)
- chromosomes (1)
- chronophin (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- cleavage (1)
- clostridium botulinum (1)
- coactivator OBF-1 (1)
- coated vesicles (1)
- cofilin (1)
- combined immunodeficiency (1)
- combined therapy (1)
- comparative genomic hybridization (1)
- complement system (1)
- complex (1)
- confocal Raman imaging (1)
- consensus DNA (1)
- cross-priming (1)
- cutaneous T-cell-lymphoma (1)
- cycle (1)
- cyclophsophamide (1)
- cyclosporine A (1)
- cytotoxicity (1)
- damage (1)
- damage responses (1)
- deformation (1)
- deletions (1)
- diagnostics (1)
- diffuse large B-cell lymphoma (1)
- diffuse large B‐cell lymphoma (1)
- disease (1)
- distinct (1)
- down regulation (1)
- drug abuse (1)
- drug resistance (1)
- drug therapy (1)
- early breast cancer (1)
- echocardiography (1)
- ectopic lymphoid follicle (1)
- ejection fraction (1)
- embryonic lethality (1)
- encephalitis lethargica (1)
- enhancer (1)
- ephitelial cells (1)
- epigenetics (1)
- epithelial markers (1)
- epithelium (1)
- extramedullary disease (1)
- features (1)
- ferroptosis (1)
- fibroblast activation protein (1)
- fixation (1)
- fluorescence in situ hybridisation (1)
- follicular T helper cells (1)
- follicular lymphoma (1)
- forecasting (1)
- formalin (1)
- functional characterization (1)
- gRNA-only (1)
- gastric bypass (1)
- gastrointestinal infections (1)
- gefitinib (1)
- genetic loci (1)
- genomic aberrations (1)
- germinal center formation (1)
- germline mutation (1)
- gesolin function (1)
- glioblastoma multiforme (GBM) (1)
- glucocorticoid excess (1)
- glutaminase inhibition (1)
- goldfish optic nerve (1)
- grade 3B (1)
- group 3 (1)
- growth (1)
- growth pattern (1)
- growth patterns (1)
- growth-associated protein (1)
- gut–liver axis (1)
- head and neck cancer (1)
- heart (1)
- heart failure (1)
- helper T cells (1)
- helper T-cells (1)
- hematopoiesis (1)
- hematopoietic stem cells (1)
- hemophagocytosis (1)
- hepcidin (1)
- high numbers (1)
- high-dose chemotherapy (1)
- high-resolution analysis (1)
- high-risk Prostate Cancer (1)
- high‐grade B‐cell lymphoma (1)
- hippocampal stem cells (1)
- hnRNP K (1)
- hormones (1)
- human (1)
- human brain (1)
- human cerebral endothelial cells (1)
- human genome (1)
- humoral immunity (1)
- hyper-IgM syndrome type 2 (HIGM2) (1)
- hypercortisolism (1)
- iiron transporter (1)
- immune cells (1)
- immune check inhibitor (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune evasion (1)
- immune infiltration (1)
- immune system (1)
- immunity (1)
- immunocytochemistry (1)
- immunofuorescence double staining (1)
- immunoglobulin promoters (1)
- immunology and microbiology section (1)
- immunotherapeutics (1)
- immunotherapy (1)
- in silico analysis (1)
- in-vitro (1)
- in-vivo (1)
- independent predictor (1)
- induction (1)
- inflammation-induced tissue demage (1)
- integrated stress response (1)
- integrin (1)
- interleukin-8 (1)
- interleukins (1)
- intestine (1)
- intraosseous (1)
- intravascular large B‐cell lymphoma (1)
- invasion (1)
- involvement (1)
- iron in parkinsonism (1)
- iron model (1)
- iron pathology (1)
- karyotype (1)
- kidney cancer (1)
- kinase (1)
- kinases (1)
- knock down (1)
- large cell transformation (1)
- latency type (1)
- lesions (1)
- leukemia (1)
- lichen planus (1)
- lineage (1)
- lineage differentiation (1)
- lipid droplets (1)
- lipids (1)
- lipoblastoma (1)
- lipoid pneumonitis (1)
- liquid biopsy (1)
- liraglutide (1)
- livin (1)
- lung fibrosis (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphocyte activation (1)
- lymphocyte differentiation (1)
- lymphocytes (1)
- lymphohistiocytosis (1)
- lymphoid aggregate (1)
- lymphoid hyperplasia (1)
- lymphoid-tissue (1)
- lymphoid-tissue lymphomas (1)
- mRNA expression (1)
- mTOR (1)
- major histocompatibility complex (1)
- malignancies (1)
- malt lymphoma (1)
- mammalian cells (1)
- mandible (1)
- mantel cell lymphoma (1)
- mantle cell lymphoma (1)
- marcophages (1)
- marrow transplantation (1)
- mass cytometry (1)
- mast cells (1)
- mastocytosis (1)
- measles virus (1)
- medical research (1)
- medicine (1)
- membrane topology (1)
- membrane translocation (1)
- memory B cells (1)
- meningeal inflammation (1)
- meningioma (1)
- mesenchymal markers (1)
- mesenteric lymph node (1)
- mesentery (1)
- messenger-RNA transport (1)
- metabolism (1)
- metagenomics (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- miR-126 (1)
- miR-21 (1)
- microRNA-221 (1)
- microglia (1)
- microvessel permeability (1)
- mitochondrial DNA (1)
- mitosis (1)
- mitotane (1)
- mitotic genes (1)
- molecular subtypes (1)
- monoclonal antibody (1)
- mouse model (1)
- mtDNA (1)
- multifocal growth (1)
- multigene-array (1)
- multiple sclerosis (1)
- multivariate data analysis (1)
- multi‐organ disease (1)
- murine homolog (1)
- mutant p53 (1)
- mutation (1)
- mutational targeting (1)
- myasthenia (1)
- myasthenia gravis (1)
- mycosis fungoides (1)
- naive T-cell gene editing (1)
- nephroblastoma (1)
- nervous system (1)
- network (1)
- neurodegeneration (1)
- neurodegenerative disease (1)
- neuroendocrine tumor (1)
- neuromelanin (1)
- neurooncology (1)
- neuropathology (1)
- neuroscience (1)
- neurotoxicity (1)
- neurovascular unit (1)
- neutral loss (1)
- next generation sequencing (1)
- niche (1)
- nodular lymphcyte (1)
- non-small cell lung cancer (1)
- noncoding RNAs (1)
- normal adrenal glands (1)
- notch signaling (1)
- obinutuzumab (1)
- olfactory bulb (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- orthotopic xenograft (1)
- outcomes research (1)
- outreach (1)
- oxidative stress (1)
- p53 (1)
- p53 expression (1)
- p53-dependent apoptosis (1)
- p53-inducible regulator (1)
- pFADD (1)
- pan-RCC (1)
- pancreatic cancer (1)
- panel sequencing (1)
- panel-sequencing (1)
- panniculitis (1)
- parathyroid carcinoma (1)
- parkinson’s disease (1)
- pathogenesis (1)
- pathology (1)
- pathway (1)
- patient access (1)
- patient survival (1)
- pediatric (1)
- pediatric lymphoma (1)
- pembrolizumab (1)
- peptide receptor radionuclide therapy (1)
- peptide receptor radionuclide therapy (PRRT) (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- peripheral T-cell (1)
- phosphatase 2A (1)
- phospholipase A(2) (1)
- plasmablasts (1)
- pleural mesothelioma (1)
- postencephalitic parkinsonism (1)
- precision oncology (1)
- prediction (1)
- primary bone marrow presentation (1)
- primary cell culture (1)
- primary cutaneous follicular B-cell lymphoma (1)
- prognostic factor (1)
- prognostic marker (1)
- prognostic value (1)
- progressive multiple sclerosis (1)
- prostate cancer (1)
- protein and mRNA expression (1)
- proteins (1)
- pseudocarcinomatous hyperplasia (1)
- pseudolymphoma (1)
- psoas muscle (1)
- psoriasis (1)
- radiation (1)
- radiation-induced migration (1)
- raman spectroscopy (1)
- rare SNP (1)
- real world data (1)
- recurrence-free survival (1)
- refractory/relapsed lymphoma (1)
- regional development (1)
- regulatory T cells (1)
- regulatory T-cells (1)
- renal cancer (1)
- renal cell carcinoma (1)
- repeated surgery (1)
- resistance (1)
- restoration (1)
- retroperitoneal tumor (1)
- reverse transcriptase-polymerase chain reaction (1)
- ribosome (1)
- ribosyltransferase (1)
- roquin (1)
- salivary gland neoplasia (1)
- salivary gland tumor (1)
- salivary gland tumors (1)
- salivary glands (1)
- scoring system (1)
- seminoma (1)
- senescence (1)
- serum (1)
- signal transduction (1)
- slice culture (1)
- somatic hypermutation (1)
- somatic mutations (1)
- spinal-cord-injury (1)
- splice variant (1)
- squamous tumors (1)
- stem cell transplantation (1)
- stem-cells (1)
- stemness (1)
- subventricular zone (1)
- suppression (1)
- suppressor (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical treatment (1)
- systemic sclerosis (1)
- t-SNE (1)
- target (1)
- target validation (1)
- targeted (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- targeted therapies (1)
- targeted therapy (1)
- tauopathy (1)
- tetraspanin (1)
- tetraspanin protein (1)
- theranostics (1)
- therapeutic target (1)
- therapy response (1)
- thiol starvation (1)
- thymic carcinoma (1)
- thymic epithelial tumor (1)
- thymitis (1)
- thymocytes (1)
- thymoma (1)
- tissue preparation (1)
- transcript (1)
- transcription factor FOXP1 (1)
- transcription factors (1)
- transcriptional repression (1)
- transcriptome (1)
- transcriptomic analysis (1)
- transformation (1)
- translocation (1)
- transplantation (1)
- trastuzumab (1)
- trastuzumab deruxtecan (1)
- treg cells (1)
- triple-negative breast cancer (1)
- tumor heterogeneity (1)
- tumor immunology (1)
- tumor slice cultures (1)
- tumor spheroids (1)
- tumor vaccination (1)
- tumor-vessel wall-interface model (1)
- tumorigenesis (1)
- tumormicroenvironment (1)
- tumors (1)
- tumour heterogeneity (1)
- tyrosine kinase inhibitor (TKI) (1)
- uPA (1)
- ubiquitin (1)
- unsupervised clustering (1)
- up regulation (1)
- vascular wall stem and progenitor cells (1)
- vascularization model (1)
- vasculogenesis (1)
- vemurafenib (1)
- venetoclax (1)
- virus–iron interaction (1)
- visual clustering (1)
- vitamin D receptor (1)
- vitamin metabolism (1)
- von Economo (1)
- whole-exome sequencing (1)
- ɑ-Synuclein and iron (1)
- α-synuclein-specific T cells (1)
Institute
- Pathologisches Institut (185) (remove)
Schriftenreihe
Sonstige beteiligte Institutionen
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (1)
- Lehrstuhl für Regeneration Muskuloskelettaler Gewebe (1)
- Muskuloskelettales Centrum Würzburg (MCW) (1)
Background
Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis.
Case presentation
We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones, lungs and liver after initial complete resection of the primary tumor. After partial hepatic resection, specimens were histologically analyzed, and a complete loss of E-cadherin adhesion molecules was found. No oncogenic target mutations were found. The patient received a combination of conventional radiotherapy and peptide receptor radionuclide therapy (PRRT). Due to aggressive tumor behavior and rapid spread of metastases, the patient deceased after initiation of treatment.
Conclusions
E-cadherin downregulation is associated with a higher probability of tumor invasion and distant metastasis formation in malignant meningioma. Up to now, the efficacy of systemic therapy, including PRRT, is very limited in malignant meningioma patients.
The cystine/glutamate antiporter xCT is an important source of cysteine for cancer cells. Once taken up, cystine is reduced to cysteine and serves as a building block for the synthesis of glutathione, which efficiently protects cells from oxidative damage and prevents ferroptosis. As melanomas are particularly exposed to several sources of oxidative stress, we investigated the biological role of cysteine and glutathione supply by xCT in melanoma. xCT activity was abolished by genetic depletion in the Tyr::CreER; Braf\(^{CA}\); Pten\(^{lox/+}\) melanoma model and by acute cystine withdrawal in melanoma cell lines. Both interventions profoundly impacted melanoma glutathione levels, but they were surprisingly well tolerated by murine melanomas in vivo and by most human melanoma cell lines in vitro. RNA sequencing of human melanoma cells revealed a strong adaptive upregulation of NRF2 and ATF4 pathways, which orchestrated the compensatory upregulation of genes involved in antioxidant defence and de novo cysteine biosynthesis. In addition, the joint activation of ATF4 and NRF2 triggered a phenotypic switch characterized by a reduction of differentiation genes and induction of pro-invasive features, which was also observed after erastin treatment or the inhibition of glutathione synthesis. NRF2 alone was capable of inducing the phenotypic switch in a transient manner. Together, our data show that cystine or glutathione levels regulate the phenotypic plasticity of melanoma cells by elevating ATF4 and NRF2.
Salivary gland tumors (SGTs) are a relevant, highly diverse subgroup of head and neck tumors whose entity determination can be difficult. Confocal Raman imaging in combination with multivariate data analysis may possibly support their correct classification. For the analysis of the translational potential of Raman imaging in SGT determination, a multi-stage evaluation process is necessary. By measuring a sample set of Warthin tumor, pleomorphic adenoma and non-tumor salivary gland tissue, Raman data were obtained and a thorough Raman band analysis was performed. This evaluation revealed highly overlapping Raman patterns with only minor spectral differences. Consequently, a principal component analysis (PCA) was calculated and further combined with a discriminant analysis (DA) to enable the best possible distinction. The PCA-DA model was characterized by accuracy, sensitivity, selectivity and precision values above 90% and validated by predicting model-unknown Raman spectra, of which 93% were classified correctly. Thus, we state our PCA-DA to be suitable for parotid tumor and non-salivary salivary gland tissue discrimination and prediction. For evaluation of the translational potential, further validation steps are necessary.
Highlights
• The integrated stress response leads to a general ATF4-dependent activation of NRF2
• ATF4 causes a CHAC1-dependent GSH depletion, resulting in NRF2 stabilization
• An elevation of NRF2 transcript levels fosters this effect
• NRF2 supports the ISR/ATF4 pathway by improving cystine and antioxidant supply
Summary
The redox regulator NRF2 becomes activated upon oxidative and electrophilic stress and orchestrates a response program associated with redox regulation, metabolism, tumor therapy resistance, and immune suppression. Here, we describe an unrecognized link between the integrated stress response (ISR) and NRF2 mediated by the ISR effector ATF4. The ISR is commonly activated after starvation or ER stress and plays a central role in tissue homeostasis and cancer plasticity. ATF4 increases NRF2 transcription and induces the glutathione-degrading enzyme CHAC1, which we now show to be critically important for maintaining NRF2 activation. In-depth analyses reveal that NRF2 supports ATF4-induced cells by increasing cystine uptake via the glutamate-cystine antiporter xCT. In addition, NRF2 upregulates genes mediating thioredoxin usage and regeneration, thus balancing the glutathione decrease. In conclusion, we demonstrate that the NRF2 response serves as second layer of the ISR, an observation highly relevant for the understanding of cellular resilience in health and disease.
Diagnosing any of the more than 30 types of T-cell lymphomas is considered a challenging task for many pathologists and currently requires morphological expertise as well as the integration of clinical data, immunophenotype, flow cytometry and clonality analyses. Even considering all available information, some margin of doubt might remain using the current diagnostic procedures. In recent times, the genetic landscape of most T-cell lymphomas has been elucidated, showing a number of diagnostically relevant mutations. In addition, recent data indicate that some of these genetic alterations might bear prognostic and predictive value. Extensive genetic analyses, such as whole exome or large panel sequencing are still expensive and time consuming, therefore limiting their application in routine diagnostic. We therefore devoted our effort to develop a lean approach for genetic analysis of T-cell lymphomas, focusing on maximum efficiency rather than exhaustively covering all possible targets. Here we report the results generated with our small amplicon-based panel that could be used routinely on paraffin-embedded and even decalcified samples, on a single sample basis in parallel with other NGS-panels used in our routine diagnostic lab, in a relatively short time and with limited costs. We tested 128 available samples from two German reference centers as part of our routine work up (among which 116 T-cell lymphomas), which is the largest routine diagnostic series reported to date. Our results showed that this assay had a very high rate of technical success (97%) and could detect mutations in the majority (79%) of tested T-cell lymphoma samples.
Idiopathic Parkinson’s disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus–subcoeruleus complex; (stage 2), the substantia nigra (SN) (stage 3), the anteromedial temporal mesocortex (MC) (stage 4), high-order sensory association areas and prefrontal fields (HC) (stage 5) and finally first-order sensory association areas, premotor areas, as well as primary sensory and motor field (FC) (stage 6). Autoimmunity might play a role in PD pathogenesis. Here we analyzed whether anti-brain autoantibodies differentially recognize different human brain areas and identified autoantigens that correlate with the above-described dissemination of PD pathology in the brain. Brain tissue was obtained from deceased individuals with no history of neurological or psychiatric disease and no neuropathological abnormalities. Tissue homogenates from different brain regions (DM, SN, MC, HC, FC) were subjected to SDS-PAGE and Western blot. Blots were incubated with plasma samples from 30 PD patients and 30 control subjects and stained with anti-IgG antibodies to detect anti-brain autoantibodies. Signals were quantified. Prominent autoantigens were identified by 2D-gel-coupled mass spectrometry sequencing. Anti-brain autoantibodies are frequent and occur both in healthy controls and individuals with PD. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen recognized in all plasma samples. GFAP immunoreactivity was highest in DM areas and lowest in FC areas with no significant differences in anti-GFAP autoantibody titers between healthy controls and individuals with PD. The anti-GFAP autoimmunoreactivity of different brain areas correlates with the dissemination of histopathological neurodegeneration in PD. We hypothesize that GFAP autoantibodies are physiological but might be involved as a cofactor in PD pathogenesis secondary to a leakage of the blood–brain barrier.
Purpose
While [\(^{18}\)F]-fluorodeoxyglucose ([\(^{18}\)F]FDG) is the standard for positron emission tomography/computed tomography (PET/CT) imaging of oral squamous cell carcinoma (OSCC), diagnostic specificity is hampered by uptake in inflammatory cells such as neutrophils or macrophages. Recently, molecular imaging probes targeting fibroblast activation protein α (FAP), which is overexpressed in a variety of cancer-associated fibroblasts, have become available and might constitute a feasible alternative to FDG PET/CT.
Methods
Ten consecutive, treatment-naïve patients (8 males, 2 females; mean age, 62 ± 9 years) with biopsy-proven OSCC underwent both whole-body [\(^{18}\)F]FDG and [\(^{68}\)Ga]FAPI-04 (FAP-directed) PET/CT for primary staging prior to tumor resection and cervical lymph node dissection. Detection of the primary tumor, as well as the presence and number of lymph node and distant metastases was analysed. Intensity of tracer accumulation was assessed by means of maximum (SUV\(_{max}\)) and peak (SUV\(_{peak}\) standardized uptake values. Histological work-up including immunohistochemical staining for FAP served as standard of reference.
Results
[\(^{18}\)F]FDG and FAP-directed PET/CT detected all primary tumors with a SUVmax of 25.5 ± 13.2 (FDG) and 20.5 ± 6.4 (FAP-directed) and a SUVpeak of 16.1 ± 10.3 ([\(^{18}\)F]FDG) and 13.8 ± 3.9 (FAP-directed), respectively. Regarding cervical lymph node metastases, FAP-directed PET/CT demonstrated comparable sensitivity (81.3% vs. 87.5%; P = 0.32) and specificity (93.3% vs. 81.3%; P = 0.16) to [\(^{18}\)F]FDG PET/CT. FAP expression on the cell surface of cancer-associated fibroblasts in both primary lesions as well as lymph nodes metastases was confirmed in all samples.
Conclusion
FAP-directed PET/CT in OSCC seems feasible. Future research to investigate its potential to improve patient staging is highly warranted.
The subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has become mandatory in the 2017 update of the WHO classification of lymphoid neoplasms and will continue to be used in the WHO 5\(^{th}\) edition. The RNA-based Lymph2Cx assay has been validated as a reliable surrogate of high-throughput gene expression profiling assays for distinguishing between GCB and ABC DLBCL and provides reliable results from formalin-fixed, paraffin-embedded (FFPE) material. This test has been previously used in clinical trials, but experience from real-world routine application is rare. We routinely applied the Lymph2Cx assay to day-to-day diagnostics on a series of 147 aggressive B-cell lymphoma cases and correlated our results with the immunohistochemical subclassification using the Hans algorithm and fluorescence in situ hybridization findings using break-apart probes for MYC, BCL2, and BCL6. The routine use of the Lymph2Cx assay had a high technical success rate (94.6%) with a low rate of failure due to poor material and/or RNA quality. The Lymph2Cx assay was discordant with the Hans algorithm in 18% (23 of 128 cases). Discordant cases were mainly classified as GCB by the Hans algorithm and as ABC by Lymph2Cx (n = 11, 8.6%). Only 5 cases (3.9%) were classified as non-GCB by the Hans algorithm and as GCB by Lymph2Cx. Additionally, 5.5% of cases (n = 7) were left unclassified by Lymph2Cx, whereas they were defined as GCB (n = 4) or non-GCB (n = 3) by the Hans algorithm. Our data support the routine applicability of the Lymph2Cx assay.
Background
Panniculitis-like T-cell lymphoma is an uncommon type of non-Hodgkin lymphoma, occurring usually in the form of nodules within the subcutaneous fat tissue of the extremities or trunk. In the literature, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is described as a distinct type of T-cell lymphoma with a variable clinical behavior, depending on molecular phenotype of T-cell receptor (TCR) and on the presence or absence of hemophagocytic syndrome.
Case presentation
We present a bioptic and autoptic case of a 65-years old Caucasian man with panniculitic T-cell lymphoma with morphological and immunohistochemical features of SPTCL, limited to the retroperitoneal and mesenteric mass, i.e. without any cutaneous involvement, and associated with severe hemophagocytic lymphohistiocytosis.
Conclusion
A panniculitic T-cell lymphoma with morphological and molecular features of SPTCL, which is limited to mesentery, i.e. does not involve subcutaneous fat, seems to be exceedingly rare.
Routine coronal paraffin-sections through the dorsal frontal and parieto-occipital cortex of a total of sixty cases with divergent causes of death were immunohistochemically (IHC) stained with an antibody against TMEM119. Samples of cerebrospinal fluid (CSF) of the same cases were collected by suboccipital needle-puncture, subjected to centrifugation and processed as cytospin preparations stained with TMEM119. Both, cytospin preparations and sections were subjected to computer-assisted density measurements. The density of microglial TMEM119-positive cortical profiles correlated with that of cytospin results and with the density of TMEM119-positive microglial profiles in the medullary layer. There was no statistically significant correlation between the density of medullary TMEM119-positive profiles and the cytospin data. Cortical microglial cells were primarily encountered in supragranular layers I, II, and IIIa and in infragranular layers V and VI, the region of U-fibers and in circumscribed foci or spread in a diffuse manner and high density over the white matter. We have evidence that cortical microglia directly migrate into CSF without using the glympathic pathway. Microglia in the medullary layer shows a strong affinity to the adventitia of deep vessels in the myelin layer. Selected rapidly fatal cases including myocardial infarcts and drowning let us conclude that microglia in cortex and myelin layer can react rapidly and its reaction and migration is subject to pre-existing external and internal factors. Cytospin preparations proved to be a simple tool to analyze and assess complex changes in the CNS after rapid fatal damage. There is no statistically significant correlation between cytospin and postmortem interval. Therefore, the quantitative analyses of postmortem cytospins obviously reflect the neuropathology of the complete central nervous system. Cytospins provide forensic pathologists a rather simple and easy to perform method for the global assessment of CNS affliction.